IDEXX Laboratories, Inc. vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 37,320,110). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| IDXX | LQD | |
|---|---|---|
Market Cap | $40.43B | $28.50B |
Volume | 692,164 | 37,320,110 |
Sector | Health | Fixed Income |
52-Week High | $766.68 | $112.91 |
52-Week Low | $504.70 | $101.83 |
Typical Hold Time | 46 Days | 125 Days |
Enterprise Value | $41.32B | — |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
LQD trades at $102.41 with a slight 0.28% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September and concerns about investment-grade corporate bonds as Treasury yields hit multi-decade highs. The fund maintains consistent dividend distributions with recent payouts around $0.44-0.46 per share.
The outlook remains cautious given the bearish technical setup and rising bond yields pressuring corporate debt valuations. Key risks include continued bond market volatility and higher borrowing costs for issuers. Investment opportunities exist for income-focused investors seeking exposure to investment-grade corporate bonds, though near-term price pressure may persist until bond market conditions stabilize.
Trailing returns across standard periods
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →